Tildrakizumab in the treatment of PASH syndrome: A potential novel therapeutic target
Australasian Journal of Dermatology2020Vol. 61(3), pp. e373–e374
Citations Over TimeTop 16% of 2020 papers
Abstract
PASH syndrome is a rare auto-inflammatory condition characterised by the presence of pyoderma gangrenosum (PG), acne and hidradenitis suppurativa (HS)(1). Management of this condition involves lifestyle approaches such as weight loss and smoking cessation, and, a combination of oral antibiotics, systemic therapies, biologics such as adalimumab and surgical procedures(2). Tildrakizumab is a monoclonal antibody which blocks interleukin-23, a cytokine critical in chronic auto-inflammation of the skin(3). Its use in the treatment of this condition has not been documented. We present a case of managing PASH syndrome with tildrakizumab in Australia.
Related Papers
- → Interleucinas na encefalopatia hipóxico-isquêmica(2003)14 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)